On March 15, 2011, MAPS submitted to the FDA the revised protocol for its planned study of smoked and/or vaporized marijuana for PTSD in war veterans. In a February 9 conference call, the FDA acknowledged …
On February 3, 2011, the U.S. FDA asked MAPS to provide additional information regarding the protocol for our planned study of the safety and effectiveness of smoked and/or vaporized marijuana for the …
On December 15, 2010, the FDA notified MAPS that our planned study of smoked or vaporized marijuana for veterans with chronic, treatment-resistant PTSD had been placed on full clinical hold until we are …
On December 15, 2010, FDA placed MAPS’ study of marijuana for people with PTSD on full clinical hold. (Letter describing study placement on clinical hold.)
On December 15, 2010, FDA placed MAPS’ study of marijuana for people with PTSD on full clinical hold. (Letter describing study placement on clinical hold.)
On December 15, 2010, FDA placed MAPS’ study of marijuana for people with PTSD on full clinical hold. (Letter describing study placement on clinical hold.)
On Nov. 11, 2010, MAPS’ clinical research team submitted our newest marijuana protocol to the FDA. If approved, the study will gather preliminary information about whether medical marijuana is a …
Julie Holland, M.D., has reviewed the protocol and agreed to be the medical monitor for our newest study of marijuana as a treatment for PTSD. The protocol was submitted to the FDA on Nov. 12, 2010, and …
MAPS received an Investigational New Drug identification number for marijuana from the FDA. This is part of our study of marijuana for PTSD.
On Oct. 3, Research and Information Specialist Ilsa Jerome, Ph.D., Clinical Research Associate Berra Yazar-Klosinski, Ph.D., and Executive Director Rick Doblin, Ph.D., finalized the study design for our …
MAPS is preparing a marijuana/PTSD pilot study in veterans of war to be conducted by Principal Investigator Sue Sisley, M.D. in Arizona. The protocol is close to being submitted to the FDA after having …
